Navigation Links
Anesthesia and Alzheimer's
Date:4/25/2008

In studies of human brain cells, the widely-used anesthetic desflurane does not contribute to increased production of amyloid-beta protein; however, when combined with low oxygen conditions, it can produce more of this Alzheimers associated protein.

Over 200 million people undergo surgery each year, and there has been concern that anesthetic use may contribute to Alzheimers and other brain disorders. Bin Zhang, Yuanlin Dong, Rudolph Tanzi, Zhongcong Xie, and colleagues examined this possibility with commonly used inhalation anesthetics isoflurane previously and desflurane more recently.

They subjected human brain cells to 12% desflurane for six hours (mimicking a surgery condition) and observed no changes in either the production of amyloid-beta protein or the rate of cell death. However, when combined with low oxygen levels (18%), desflurane could stimulate these cellular changes associated with Alzheimers (hypoxia by itself did not induce any changes). The results with desflurane are contrary to the researchers previous work, which found isoflurane by itself could stimulate both amyloid production and cell death.

The researchers do emphasize that the current findings are from cell culture experiments, and the next critical step will be to confirm these findings in animal models and test the effects of other anesthetic agents. But, these early results suggest that it is important to ensure anesthetic patients maintain sufficient oxygen in their brain.


'/>"/>

Contact: Nick Zagorski
nzagorski@asbmb.org
301-634-7366
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1

Related biology news :

1. Paradigm shift in Alzheimerss research: new treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: